Gordon Freeman, Ph.D.  •  Lee Nadler, M.D.

C0376  Tumor Cells Modified with Increased Immunogenicity (US6723705, US5861310)  
Gordon Freeman, Ph.D.  •  Lee Nadler, M.D.

Gordon Freeman, Ph.D.  •  Lee Nadler, M.D.

C0653  Method of attenuating reactions to skin irritants (PCT/US2002/009378)  
Glenn Dranoff, M.D.

C0989  Regulation of Runx1 for Treatment of Pain (PCT/US2006/007578)  
Qiufu Ma, Ph.D.

C1171  Prognostic, Diagnostic, and Cancer Therapeutic Uses of Fancl and Fancl Modulating Agents (PCT/US2008/003150)  
Alan D’Andrea, M.D.

C1177  MFG-E8 Inhibition in Vaccination Against Cancer (PCT/US2007/080446)  
Glenn Dranoff, M.D.

C1155  Small Molecule Modulators of STAT function (Non-Oncology, Non-Dermatology Fields Only) (PCT/US2008/007349)  
David Frank, M.D., Ph.D.

C1198  Methods for the Modulation of Immune Responses using Galectin-1 (PCT/US2008/070324)  
Margaret Shipp, M.D.

C1316  Anti-Galectin-1 Monoclonal Antibodies (PCT/US2010/056547)  
Margaret Shipp, M.D.

C1351  MUC-1 Inhibitors as Anti-inflammatory Agents (PCT/US2010/036436)  
Donald Kufe

C1431  Inhibitors of USP1 Deubiquinating Enzyme Complex (PCT/US2011/034514)  
Alan D’Andrea, M.D.

For more information, please contact the Innovation Office at DFCI: innovation@dfci.harvard.edu
Therapeutic Opportunities

C1688  Compositions and Methods of Treating MUC16-expressing Cancer (PCT/US2014/026408)
       Donald Kufe, M.D.

C1725  Compositions and Methods for Identification, Assessment, Prevention, and Treatment of Cancer Using Histone H3K27ME3 Biomarkers and Modulators (PCT/US2014/038938)
       Andrew Lane, M.D., Ph.D. • David Weinstock, M.D.

C1745  Intranuclear Osteopontin Regulates the Lineage Commitment of Lymphoid Subsets (PCT/US2015/047189)
       Harvey Cantor, M.D.

C1767  Atovaquone as a STAT3 Inhibitor and Anti-cancer Agent (PCT/US2014/058203)
       David Frank, M.D., Ph.D.

C1832  The PI3K-mTOR-S6K1 Axis Governs Essential 5’UTR-Dependent, eIF4A-Mediated Translation of c-MYC mRNA in MYC-dependent Neoplasia (PCT/US2015/015544)
       Jean Zhao, Ph.D.

C1866  Methods for Treating Cancer with Anti-BiP or Anti-MICA Antibodies (PCT/US2015/031951)
       Kai Wucherpfennig, M.D., Ph.D. • Glenn Dranoff, M.D.

C1870  Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response (PCT/US2015/027515)
       Kwok-Kin Wong, M.D., Ph.D.

C1876  Use of Tim3 Blocking Antibodies to Overcome Resistance to PD1 Blockade (PCT/US2015/039379)
       Kwok-Kin Wong, M.D., Ph.D.

C1906  Compositions and Methods for Treating Multiple Myeloma (PCT/US2015/056347)
       Kenneth Anderson, M.D.

For more information, please contact the Innovation Office at DFCI: innovation@dfci.harvard.edu
Therapeutic Opportunities

C1917  Multiple-Variable IL-2 Dose Regimen for Treating Immune Disorders (PCT/US2015/054466)
John Koreth, M.D., Ph.D. • Jerome Ritz, M.D. • Robert Soiffer, M.D.

C1950  Methods of Treating Cancer Comprising Administering a PPAR-gamma Agonist (PCT/US2015/048925)
Glenn Dranoff, M.D.

C1986  CDK7 Inhibition Blocks Adaptive and Acquired Resistance to Kinase Inhibitors (PCT/US2016/037086)
Nathanael Gray, Ph.D. • Peter Hammerman, M.D., Ph.D. • Kwok-Kin Wong, M.D., Ph.D.

C2048  Fusion Protein for Cancer Immunotherapy (PCT/US2016/061479)
Glenn Dranoff, M.D.

C2109  Genome Editing of CD8 T Cells to Prevent T Cell Exhaustion (Provisional Filed)
W. Nicholas Haining, B.M., B.Ch.

C2117  Nanoparticles that Target Immunotherapy to Specific Subsets of Endogenous Immune Cells (PCT Filed)
Michael Goldberg, Ph.D.

C2192  Drivers of Endocrine Resistance and Synthetic Lethal Vulnerabilities in Breast Cancer (Provisional Filed)
Xiaole Shirley Liu, Ph.D. • Myles Brown, M.D.

For more information, please contact the Innovation Office at DFCI:
innovation@dfci.harvard.edu